CL2021002669A1 - (divisional de solicitud 3443-2018) tratamientos de cancer. - Google Patents

(divisional de solicitud 3443-2018) tratamientos de cancer.

Info

Publication number
CL2021002669A1
CL2021002669A1 CL2021002669A CL2021002669A CL2021002669A1 CL 2021002669 A1 CL2021002669 A1 CL 2021002669A1 CL 2021002669 A CL2021002669 A CL 2021002669A CL 2021002669 A CL2021002669 A CL 2021002669A CL 2021002669 A1 CL2021002669 A1 CL 2021002669A1
Authority
CL
Chile
Prior art keywords
treatment
protide
cancer
methods
medical uses
Prior art date
Application number
CL2021002669A
Other languages
English (en)
Inventor
Hugh Griffith
Chris Mcguigan
Chris Peper
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NuCana plc filed Critical NuCana plc
Publication of CL2021002669A1 publication Critical patent/CL2021002669A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan usos médicos y métodos para atacar focalizadamente a células madre cancerosas empleando compuestos ProTide, particularmente en la prevención o el tratamiento del cáncer. El ProTide puede ser distinto de uno seleccionado del grupo consistente en: NUC-1031; un ProTide derivado de cordicepina; y un ProTide derivado de 8-cloroadenosina. Los usos médicos y métodos para atacar focalizadamente a células madre cancerosas son particularmente útiles en el tratamiento de un cáncer recidivante o refractario en pacientes humanos. La invención también proporciona métodos para seleccionar pacientes que se beneficiarán de la prevención o el tratamiento del cáncer mediante los usos médicos o métodos de tratamiento de la invención.
CL2021002669A 2016-06-01 2021-10-12 (divisional de solicitud 3443-2018) tratamientos de cancer. CL2021002669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1609600.0A GB201609600D0 (en) 2016-06-01 2016-06-01 Cancer treatments

Publications (1)

Publication Number Publication Date
CL2021002669A1 true CL2021002669A1 (es) 2022-05-27

Family

ID=56410849

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018003443A CL2018003443A1 (es) 2016-06-01 2018-11-30 Tratamientos para el cancer.
CL2021002669A CL2021002669A1 (es) 2016-06-01 2021-10-12 (divisional de solicitud 3443-2018) tratamientos de cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018003443A CL2018003443A1 (es) 2016-06-01 2018-11-30 Tratamientos para el cancer.

Country Status (18)

Country Link
US (2) US11400107B2 (es)
EP (1) EP3463384A1 (es)
JP (2) JP7367910B2 (es)
KR (2) KR20190011770A (es)
CN (1) CN109562119A (es)
AU (1) AU2017273124B2 (es)
BR (1) BR112018074981A2 (es)
CA (1) CA3025442C (es)
CL (2) CL2018003443A1 (es)
EA (1) EA038030B1 (es)
GB (1) GB201609600D0 (es)
IL (1) IL263123B (es)
MA (1) MA45129A (es)
MX (1) MX2018014840A (es)
MY (1) MY199129A (es)
PH (1) PH12018502491A1 (es)
SG (1) SG11201810196RA (es)
WO (1) WO2017207993A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2686219T3 (es) 2011-03-01 2018-10-16 NuCana plc Compuestos químicos
MX2017006942A (es) 2014-11-28 2017-08-24 Nucana Biomed Ltd Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
TW202322824A (zh) 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2007056596A2 (en) 2005-11-09 2007-05-18 Wayne State University Phosphoramidate derivatives of fau
PL2200431T3 (pl) 2007-09-10 2017-01-31 Boston Biomedical Inc Nowe kompozycje i metody służące leczeniu raka
EP2385370A1 (en) 2008-04-10 2011-11-09 Massachusetts Institute of Technology (MIT) Methods for identification and use of agents targeting cancer stem cells
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
ES2686219T3 (es) 2011-03-01 2018-10-16 NuCana plc Compuestos químicos
CA2947939A1 (en) 2014-05-28 2015-12-03 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
TWI695718B (zh) * 2014-06-25 2020-06-11 英商努卡那公眾有限公司 前藥
AU2015278900B2 (en) * 2014-06-25 2019-04-04 NuCana plc Formulation comprising a gemcitabine-prodrug
MX2017006942A (es) * 2014-11-28 2017-08-24 Nucana Biomed Ltd Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
EP3415149A1 (en) * 2015-05-14 2018-12-19 NuCana plc Cancer treatments
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis

Also Published As

Publication number Publication date
KR20190011770A (ko) 2019-02-07
WO2017207993A1 (en) 2017-12-07
JP7367910B2 (ja) 2023-10-24
CL2018003443A1 (es) 2019-08-09
CA3025442A1 (en) 2017-12-07
SG11201810196RA (en) 2018-12-28
MX2018014840A (es) 2019-03-14
US11400107B2 (en) 2022-08-02
EA038030B1 (ru) 2021-06-25
GB201609600D0 (en) 2016-07-13
AU2017273124B2 (en) 2022-09-29
CA3025442C (en) 2024-02-20
IL263123B (en) 2022-09-01
EA201892803A1 (ru) 2019-06-28
MA45129A (fr) 2021-05-05
IL263123A (en) 2018-12-31
JP2019521971A (ja) 2019-08-08
JP2022051965A (ja) 2022-04-01
MY199129A (en) 2023-10-17
AU2017273124A1 (en) 2018-12-13
CN109562119A (zh) 2019-04-02
US20230218655A1 (en) 2023-07-13
PH12018502491A1 (en) 2019-09-09
EP3463384A1 (en) 2019-04-10
BR112018074981A2 (pt) 2019-03-12
US20190374564A1 (en) 2019-12-12
KR20220142538A (ko) 2022-10-21

Similar Documents

Publication Publication Date Title
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
EA201890961A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
MX2022008868A (es) Tratamiento del cancer con tg02.
PE20180260A1 (es) Metodos y kits para tratar la depresion
MX2017013142A (es) Terapia combinada para tratar cáncer.
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
MX2020009154A (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
GT201700163A (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatía dilatada (mcd)
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
CO2022000481A2 (es) Inhibidores de enzimas
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2021001612A (es) Compuestos utiles en terapia del vih.